Literature DB >> 15632833

Immunophilin ligands FK506 and cyclosporine A improve neurologic and histopathologic outcome after transient spinal cord ischemia in rabbits.

Tsuyoshi Tachibana1, Norihiko Shiiya, Takashi Kunihara, Yutaka Wakamatsu, Akimaro Fabio Kudo, Tomonori Ooka, Satoshi Watanabe, Keishu Yasuda.   

Abstract

BACKGROUND: We comparatively evaluated the protective effect of the immunophilin ligands cyclosporine A (INN: ciclosporin), FK506, and rapamycin on the spinal cord in a rabbit model of transient ischemia. Both cyclosporine A and FK506 inhibit calcineurin, whereas rapamycin does not.
METHODS: Thirty-six male New Zealand White rabbits were divided into the following 6 groups: group C, 15 minutes of spinal cord ischemia; group FK, FK506 (1 mg/kg) administered 30 minutes before ischemia; group CsA, cyclosporine A (30 mg/kg) administered 30 minutes before ischemia; group CsA-C, chronic administration of cyclosporine A (20 mg/kg) for 9 days before ischemia; group R, rapamycin (1 mg/kg) administered 30 minutes before ischemia; and group R+FK, rapamycin (1 mg/kg) administered 20 minutes before FK506 pretreatment (1 mg/kg). Group CsA-C was added because the drug does not readily cross the blood-brain barrier. Neurologic function was evaluated by Johnson's 5-point scale at 8, 24, and 48 hours after ischemia, and histopathology was assessed 48 hours after ischemia.
RESULTS: At 24 and 48 hours after ischemia, the Johnson score was better in groups FK (4.0 +/- 1.1), R+FK (3 +/- 1.1), and CsA-C (2.7 +/- 1.2) than in group C (0.8 +/- 1.2). Numbers of morphologically intact anterior horn cells were higher in groups FK (31.3 +/- 9.9), R+FK (23.2 +/- 4.5), and CsA-C (18.3 +/- 6.8) than in group C (6.3 +/- 4.3).
CONCLUSIONS: FK506 and chronic administration of cyclosporine A, but not rapamycin, protect the spinal cord from transient ischemia. Although these results are compatible with inhibition of calcineurin in the mechanism of neuroprotective action of these drugs, other effects through different pathways cannot be excluded before further study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15632833     DOI: 10.1016/j.jtcvs.2004.04.047

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition.

Authors:  Bradley G Leshnower; Shinya Kanemoto; Muneaki Matsubara; Hiroaki Sakamoto; Robin Hinmon; Joseph H Gorman; Robert C Gorman
Journal:  Ann Thorac Surg       Date:  2008-10       Impact factor: 4.330

2.  Impact of acquired and innate immunity on spinal cord ischemia and reperfusion injury.

Authors:  Katsuhiro Yamanaka; Naoto Sasaki; Yasuyuki Fujita; Atsuhiko Kawamoto; Ken-ichi Hirata; Yutaka Okita
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-02-19

3.  The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord.

Authors:  Simone Codeluppi; Camilla I Svensson; Michael P Hefferan; Fatima Valencia; Morgan D Silldorff; Masakatsu Oshiro; Martin Marsala; Elena B Pasquale
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

4.  Effects of long-term FK506 administration on functional and histopathological outcome after spinal cord injury in adult rat.

Authors:  Kamila Saganová; Judita Orendácová; Igor Sulla; Peter Filipcík; Dása Cízková; Ivo Vanický
Journal:  Cell Mol Neurobiol       Date:  2009-04-07       Impact factor: 5.046

Review 5.  Lymphocytes and ischemia-reperfusion injury.

Authors:  Douglas Linfert; Tayseer Chowdhry; Hamid Rabb
Journal:  Transplant Rev (Orlando)       Date:  2009-01       Impact factor: 3.943

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.